Fractyl Health Q2 FY26 net loss narrows to $25.5 million; adjusted EBITDA loss improves to $16.3 million

• Fractyl Health posted a Q2 net loss of $25.5 million, narrowing from a $27.9 million loss a year earlier.
• R&D expense fell 34.43% to $13.8 million, while SG&A rose 8.16% to $5.3 million.
• Non-GAAP adjusted EBITDA improved to negative $16.3 million from negative $24.0 million.
• Cash and cash equivalents totaled $47.1 million as of June 30, with runway guidance into early 2027.
• REMAIN-1 Pivotal Cohort topline 6-month randomized data remain on track for early Q4 2026, supporting a potential FDA De Novo submission in late Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-342343), on August 10, 2026, and is solely responsible for the information contained therein.